Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
Panel unanimously advances bill to allow in‑state processing of certain non‑embryonic stem‑cell therapies
Loading...
Summary
House Bill 1275 would permit Georgia-based processing of therapies derived from donated umbilical cord and placental tissue, exclude embryonic/fetal‑derived material, and leave federally regulated research unchanged; witnesses praised potential benefits while fertility advocates urged clearer language to avoid unintended effects on IVF and embryo care.
Representative Newton told the committee that House Bill 1275 is intended to allow manufacturing and processing in Georgia of certain stem‑cell therapies derived from donated placenta and umbilical cord tissue currently sourced from out of state. "This allows producers to obtain and process this material in the state as well," Newton said, emphasizing the bill excludes material derived from aborted fetuses or embryos and does not alter federally approved research overseen by institutional review boards.
Bridal Khateeb, director at Pointe Therapeutics, described the processing and safety testing steps she performs and told the committee the work "goes through three different rounds of testing" and that the company follows FDA standards for testing and stability. "We do additional hepatitis testing...and after the extraction process, we do a third round of testing to make sure the product is safe for our clients," she said.
But Lynn Goldman, president of the Georgia Fertility Network, urged the committee to remove the word "embryo" from the bill to avoid ambiguity that could affect IVF procedures, embryo disposition, or embryo biopsy. She warned ambiguous language could have a chilling effect on legitimate fertility care and federally compliant research. Mike Griffin of the Georgia Baptist Mission Board supported the bill's ethical language that excludes fetal‑derived stem cells.
The committee adopted two drafting corrections offered by the author (removing an inadvertent line and omitting a referenced accrediting organization) and voted unanimously to report the substitute as amended.
Supporters argued the change will shorten logistics and reduce risks from transporting tissue across state lines; critics urged narrower language to prevent unintended consequences for fertility care and federally regulated research. The measure advances out of committee.
